Procyrion has announced the presentation of studies at the Transcatheter Cardiovascular Therapeutics annual meeting (TCT 2021, 4–6 November, Orlando USA and virtual) relating to its Aortix percutaneous mechanical circulatory support device. The presentations include a spotlight on the company’s first US case treating a patient with heart failure (HF) and worsening renal function (WRF), a condition known as cardiorenal syndrome (CRS).
The Aortix device is percutaneously placed in the descending thoracic aorta for up to seven days to simultaneously unload and rest the heart and increase perfusion of the kidneys. The innovative design uses intra-aortic placement and harnesses fluid entrainment to pump blood without valves and allows for physiologically natural delivery of therapy. Use of the system can easily integrate into practices as the pump can be deployed in less than 10 minutes and device operation does not require large or expensive capital equipment, Procyrion said in a press release.
“We are excited to be included in the TCT programme this year, which represents the culmination of a number of significant milestones for the company leading up to the initiation of our IDE clinical study of the Aortix system in cardiorenal syndrome patients,” commented Eric S Fain, president and chief executive officer of Procyrion. “The first US case being presented highlights Aortix’s potential to fill the large unmet need for CRS patients, a population who suffer high mortality and readmission rates due to a lack of effective treatment options. We look forward to the presentation of this case as well as the other presentations highlighting Aortix’s unique ability to simultaneously improve cardiac and renal function for patients.”
